Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1483993

Successful Remission with Upadacitinib in a young Patient with Anti-TNF-Refractory Intestinal Behçet's disease

Provisionally accepted
Sumei Sha Sumei Sha 1Bin Xu Bin Xu 2*Kairuo Wang Kairuo Wang 1Chenyang Qiao Chenyang Qiao 1*Haitao Shi Haitao Shi 1Jiong Jiang Jiong Jiang 1*Quan Xiaojing Quan Xiaojing 1Xin Liu Xin Liu 1*
  • 1 Xi'an Jiaotong University, Xi'an, China
  • 2 Air Force Medical University, Xi'an, Shaanxi Province, China

The final, formatted version of the article will be published soon.

    The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians.Case Presentation: In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.

    Keywords: Intestinal Behçet's disease, Upadacitinib, case report, mucosal healing, Anti-TNF-Refractory

    Received: 21 Aug 2024; Accepted: 18 Oct 2024.

    Copyright: © 2024 Sha, Xu, Wang, Qiao, Shi, Jiang, Xiaojing and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bin Xu, Air Force Medical University, Xi'an, 710032, Shaanxi Province, China
    Chenyang Qiao, Xi'an Jiaotong University, Xi'an, 710049, China
    Jiong Jiang, Xi'an Jiaotong University, Xi'an, 710049, China
    Xin Liu, Xi'an Jiaotong University, Xi'an, 710049, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.